Summary of Dentsply Sirona's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $898 million, down 4.1% year-over-year (6.3% decline on a constant currency basis). Adjusted for Byte and planned dealer inventory reduction, revenue declined 3.6% on a constant currency basis.

Adjusted EBITDA Margins: Approximately flat year-over-year, supported by $44 million in tariff refunds, offset by lower gross profit due to volume declines and sales mix.

Operating Cash Flow: Increased to $99 million from $48 million in the prior year, primarily due to tariff refunds and improved working capital management.

Adjusted EPS: Flat at $0.52, with tariff refunds contributing a positive $0.17 per share.

Net Debt to EBITDA Ratio: Remained stable at 3.2x.

Share Repurchase: 1.3 million shares repurchased at an average price below $10 per share, marking the first repurchase since Q3 2024.

2Strategic Updates and Business Highlights

Leadership Changes: John C. Fortson joined as CFO, emphasizing a disciplined turnaround strategy focused on operational excellence and long-term value creation.

Return to Growth Action Plan: Six months into the plan, the company is focused on customer engagement, improving execution, and investing in sales, marketing, and R&D.

Clinical Education Initiatives: Significant investments in clinical education and sales force training, with successful events like the Global Implant Summit.

International Growth: Positive momentum in APAC with double-digit growth in milling systems and expansion of education programs.

Wellspect Healthcare: Continued strong performance driven by new product sales and geographic expansion.

3Forward Guidance and Outlook

2026 Revenue Guidance: Maintained at $3.5 billion to $3.6 billion, with adjusted EPS expected in the range of $1.40 to $1.50 (excluding tariff refunds).

Q3 Expectations: Anticipated sequential revenue decline due to normal seasonality and lower earnings compared to Q2, excluding tariff refund benefits.

Long-term Growth: Investments expected to yield visible benefits beginning in Q4 2026.

4Bad News, Challenges, or Points of Concern

Revenue Declines: Notable declines in various segments, particularly OIS (down 13.2% as reported) and EDS (down 2.7% as reported), driven by lower volumes and inventory adjustments.

Market Uncertainties: Softening demand in EMEA for capital equipment due to geopolitical tensions and economic conditions.

Operational Challenges: Ongoing need to improve execution and customer engagement, with some parts of the business improving faster than others.

Competitive Pressures: Concerns about lagging behind competitors in the U.S. market, particularly in the implants segment.

5Notable Q&A Insights

Leadership Confidence: John Fortson expressed excitement about the company's turnaround plan and the leadership team’s commitment.

Market Dynamics: Management indicated that while overall market growth is stabilizing, their guidance reflects a focus on internal execution rather than relying on market conditions.

Distributor Relationships: New partnerships in the U.S. are expected to enhance market access, though the impact on inventory levels and sales is still being monitored.

China Market: The company is cautious about the impact of VBP 2.0 in China, with no significant changes expected in the near term.

Clinical Education ROI: Investments in clinical education are seen as critical for long-term growth, with expected benefits materializing over time rather than immediately. This summary encapsulates the key points from Dentsply Sirona's Q2 2026 earnings call, providing a balanced view of the company's performance, strategic direction, and challenges ahead.